Trial Profile

A Phase 1b/2 clinical trial of Annamycin for the treatment of STS lung metastases in the U.S

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naxtarubicin (Primary)
Indications Cancer metastases; Soft tissue sarcoma
Focus Adverse reactions; Therapeutic Use
Sponsors Moleculin Biotech

Most Recent Events

24 Mar 2025 According to moleculin media release, the company announced that the clinical study report is finalized but not yet filed and is expected to be released by the end of April 2025.
08 Jan 2025 According to moleculin media release, study database is locked, and the clinical study report is being written and should be completed in early 2025 and will be released in detail at that time.
08 Jan 2025 According to moleculin media release, the company completed enrollment in the Phase 2 portion

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com